141 related articles for article (PubMed ID: 33738713)
1. Clinical Outcomes and Immune Metrics in Intratumoral Basophil-Enriched Gastric Cancer Patients.
He X; Cao Y; Gu Y; Fang H; Wang J; Liu X; Lv K; Yu K; Fei Y; Lin C; Liu H; Zhang H; Li H; Xu J; Li R; He H
Ann Surg Oncol; 2021 Oct; 28(11):6439-6450. PubMed ID: 33738713
[TBL] [Abstract][Full Text] [Related]
2. Association of peripheral basophils with tumor M2 macrophage infiltration and outcomes of the anti-PD-1 inhibitor plus chemotherapy combination in advanced gastric cancer.
Wu C; Qiu Y; Zhang R; Li X; Liang H; Wang M; Li F; Zhu M; Ye G; Liu H; Li G; Zhao L
J Transl Med; 2022 Sep; 20(1):386. PubMed ID: 36058929
[TBL] [Abstract][Full Text] [Related]
3. Poor clinical outcomes of intratumoral dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin-positive macrophages associated with immune evasion in gastric cancer.
Liu X; Cao Y; Li R; Gu Y; Chen Y; Qi Y; Lv K; Wang J; Yu K; Lin C; Liu H; Zhang H; He H; Chen L; Zhang P; Shen Z; Qin J; Sun Y; Li H; Huang H; Zhang W; Xu J
Eur J Cancer; 2020 Mar; 128():27-37. PubMed ID: 32109848
[TBL] [Abstract][Full Text] [Related]
4. Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients.
Jin K; Cao Y; Gu Y; Fang H; Fei Y; Wang J; Liu X; Lv K; He X; Lin C; Liu H; Li H; He H; Li R; Zhang H; Xu J
Oncoimmunology; 2021 Apr; 10(1):1915560. PubMed ID: 33996266
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating podoplanin
Liu X; Cao Y; Lv K; Gu Y; Jin K; He X; Fang H; Fei Y; Shi M; Lin C; Liu H; Li H; He H; Xu J; Li R; Zhang H
Oncoimmunology; 2020 Nov; 9(1):1845038. PubMed ID: 33235820
[TBL] [Abstract][Full Text] [Related]
6. Latency-associated Peptide Identifies Immunoevasive Subtype Gastric Cancer With Poor Prognosis and Inferior Chemotherapeutic Responsiveness.
Cao Y; He H; Li R; Liu X; Chen Y; Qi Y; Yu K; Wang J; Lin C; Liu H; Zhang H; Li H; Chen L; Zhang P; Shen Z; Huang H; Sun Y; Zhang W; Qin J; Xu J
Ann Surg; 2022 Jan; 275(1):e163-e173. PubMed ID: 32511132
[TBL] [Abstract][Full Text] [Related]
7. Poor Clinical Outcomes and Immunoevasive Contexture in Intratumoral IL-10-Producing Macrophages Enriched Gastric Cancer Patients.
Zhang H; Li R; Cao Y; Gu Y; Lin C; Liu X; Lv K; He X; Fang H; Jin K; Fei Y; Chen Y; Wang J; Liu H; Li H; Zhang H; He H; Zhang W
Ann Surg; 2022 Apr; 275(4):e626-e635. PubMed ID: 32541216
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral Foxp3
Fei Y; Cao Y; Gu Y; Fang H; Chen Y; Wang J; Liu X; Lv K; He X; Lin C; Liu H; Li H; He H; Li R; Zhang H; Zhang W
Cancer Immunol Immunother; 2022 Jan; 71(1):1-11. PubMed ID: 33978826
[TBL] [Abstract][Full Text] [Related]
9. Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer.
He X; Gu Y; Cao Y; Hu B; Fang H; Fei Y; Lv K; Liu X; Wang J; Lin C; Liu H; Zhang H; Li H; Li R; He H; Xu J
Eur J Cancer; 2021 Nov; 157():114-123. PubMed ID: 34508993
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral CD103
Gu Y; Chen Y; Jin K; Cao Y; Liu X; Lv K; He X; Lin C; Liu H; Li H; He H; Qin J; Li R; Zhang H; Zhang W
Oncoimmunology; 2020 Nov; 9(1):1844402. PubMed ID: 33312758
[TBL] [Abstract][Full Text] [Related]
11. Tumor-infiltrating Neutrophils is Prognostic and Predictive for Postoperative Adjuvant Chemotherapy Benefit in Patients With Gastric Cancer.
Zhang H; Liu H; Shen Z; Lin C; Wang X; Qin J; Qin X; Xu J; Sun Y
Ann Surg; 2018 Feb; 267(2):311-318. PubMed ID: 27763900
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral IL17-producing cells infiltration correlate with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer.
Wang JT; Li H; Zhang H; Chen YF; Cao YF; Li RC; Lin C; Wei YC; Xiang XN; Fang HJ; Zhang HY; Gu Y; Liu X; Zhou RJ; Liu H; He HY; Zhang WJ; Shen ZB; Qin J; Xu JJ
Ann Oncol; 2019 Feb; 30(2):266-273. PubMed ID: 30445581
[TBL] [Abstract][Full Text] [Related]
13. Impact of intratumoural CD96 expression on clinical outcome and therapeutic benefit in gastric cancer.
Xu C; Fang H; Gu Y; Yu K; Wang J; Lin C; Zhang H; Li H; He H; Liu H; Li R
Cancer Sci; 2022 Dec; 113(12):4070-4081. PubMed ID: 35997524
[TBL] [Abstract][Full Text] [Related]
14. Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin
Zhou Q; Wang Z; Zeng H; Zhang H; Liu Z; Huang Q; Wang J; Chang Y; Bai Q; Liu L; Zhu Y; Xu L; Dai B; Guo J; Xia Y; Wang Y; Xu J
Oncoimmunology; 2020 Apr; 9(1):1747333. PubMed ID: 33457092
[TBL] [Abstract][Full Text] [Related]
15. TIM3
Chen K; Gu Y; Cao Y; Fang H; Lv K; Liu X; He X; Wang J; Lin C; Liu H; Zhang H; He H; Xu J; Li H; Li R
Br J Cancer; 2022 Jan; 126(1):100-108. PubMed ID: 34725458
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral IL-1R1 expression delineates a distinctive molecular subset with therapeutic resistance in patients with gastric cancer.
Zhang P; Gu Y; Fang H; Cao Y; Wang J; Liu H; Zhang H; Li H; He H; Li R; Lin C; Xu J
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110359
[TBL] [Abstract][Full Text] [Related]
17. Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer.
Xia S; Gu Y; Zhang H; Fei Y; Cao Y; Fang H; Wang J; Lin C; Zhang H; Li H; He H; Xu J; Li R; Liu H; Zhang W
Oncoimmunology; 2021; 10(1):1975386. PubMed ID: 34552824
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral IL22-producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responses.
Zeng H; Liu Z; Wang Z; Zhou Q; Qi Y; Chen Y; Chen L; Zhang P; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Dai B; Guo J; Xu L; Zhang W; Xu J
Int J Cancer; 2020 Jan; 146(2):542-552. PubMed ID: 31584197
[TBL] [Abstract][Full Text] [Related]
19. Poor clinical outcomes and immunoevasive contexture in SIRPα
Xu Z; Zeng H; Liu Z; Jin K; Chang Y; Wang Y; Liu L; Zhu Y; Xu L; Wang Z; Guo J; Xu J
Urol Oncol; 2022 Mar; 40(3):109.e11-109.e20. PubMed ID: 34600802
[TBL] [Abstract][Full Text] [Related]
20. C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer.
Wu S; He H; Liu H; Cao Y; Li R; Zhang H; Li H; Shen Z; Qin J; Xu J
Oncoimmunology; 2018; 7(6):e1433517. PubMed ID: 29872564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
